Page 159 - Read Online

Page 174 Kumar et al. Cancer Drug Resist 2019;2:161-77 I http://dx.doi.org/10.20517/cdr.2018.27

cancer therapy resistance through WNT16B. Nat Med 2012;18:1359-68.
41. Kang J, Kim W, Kwon T, Youn H, Kim JS, et al. Plasminogen activator inhibitor-1 enhances radioresistance and aggressiveness of non-
small cell lung cancer cells. Oncotarget. 2016;7:23961-74.
42. Peters GJ, Kohne CH. Fluoropyrimidines as antifolate drugs. In Antifolate Drugs in Cancer Therapy. Totowa, NJ: Humana Press; 1999.
pp. 101-45.
43. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
44. Marsh S, McLeod HL. Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer 2001;1:175-8.
45. Longley DB, Ferguson PR, Boyer J, Latif T, Lynch M, et al. Characterization of a thymidylate synthase (TS)-inducible cell line: a
model system for studying sensitivity to TS-and non-TS-targeted chemotherapies. Clin Cancer Res 2001;7:3533-9.
46. Longley DB, Boyer J, Allen WL, Latif T, Ferguson PR, et al. The role of thymidylate synthase induction in modulating p53-regulated
gene expression in response to 5-fluorouracil and antifolates. Cancer Res 2002;62:2644-9.
47. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol
2002;13:1841-51.
48. Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell
lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004;10:2158-67.
49. Deffie AM, McPherson JP, Gupta RS, Hedley DW, Goldenberg GJ. Multifactorial resistance to antineoplastic agents in drug-resistant
P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II. Biochem
Cell Biol 1992;70:354-64.
50. Friche E, Danks MK, Schmidt CA, Beck WT. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.
Cancer Res 1991;51:4213-8.
51. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
52. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel
(Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-25.
53. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low
concentrations. Proc Natl Acad Sci U S A 1993;90:9552-6.
54. Burkhart CA, Kavallaris M, Horwitz SB. The role of β-tubulin isotypes in resistance to antimitotic drugs. BBA-Rev Cancer 2001;2:O1-
9.
55. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins
that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-25.
56. Stover EH, Konstantinopoulos PA, Matulonis UA, Swisher EM. Biomarkers of response and resistance to DNA repair targeted
therapies. Clin Cancer Res 2016;22:5651-60.
57. Tanaka M, Okazaki T, Suzuki H, Abbruzzese JL, Li D. Association of multi-drug resistance gene polymorphisms with pancreatic
cancer outcome. Cancer 2011;117:744-51.
58. Rodrigues AS, Gomes BC, Martins C, Gromicho M, Oliveira NG, et al. DNA repair and resistance to cancer therapy. In: Chen C, editor.
New research directions in DNA repair. IntechOpen 2013. Available from: https://www.intechopen.com/books/new-research-directions-
in-dna-repair/dna-repair-and-resistance-to-cancer-therapy. [Last accessed on 7 Jan 2019]
59. Faragher AJ, Fry AM. Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles. Mol
Biol Cell 2003;14:2876-89.
60. Zhou W, Yang Y, Xia J, Wang H, Salama ME, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and
is associated with poor prognosis in myeloma and other cancers. Cancer Cell 2013;23:48-62.
61. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, et al. Low ERCC1 expression correlates with prolonged survival after
cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.
62. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione
S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007;18:504-9.
63. Usanova S, Piée-Staffa A, Sied U, Thomale J, Schneider A, et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in
interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 2010;9:1-11.
64. Tazi J, Bakkour N, Stamm S. Alternative splicing and disease. BBA-Mol Basis Dis 2009;1792:14-26.
65. Marani M, Tenev T, Hancock D, Downward J, Lemoine NR. Identification of novel isoforms of the BH3 domain protein Bim which
directly activate Bax to trigger apoptosis. Mol Cell Biol 2002;22:3577-89.
66. de Necochea-Campion R, Shouse GP, Zhou Q, Mirshahidi S, Chen CS. Aberrant splicing and drug resistance in AML. J Hematol Oncol
2016;9:1-9.
67. Passiglia F, Listı` A, Castiglia M, Perez A, Rizzo S, et al. EGFR inhibition in NSCLC: New findings . . . . and opened questions? Crit
Rev Oncol Hematol 2017;112:126-35.
68. Stark M, Wichman C, Avivi I, Assaraf YG. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate
resistance in leukemia. Blood 2009;113:4362-9.
69. Wang Z, Wu Z, Liu Y, Han W. New development in CAR-T cell therapy. J Hematol Oncol 2017;10:1-11.
70. Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, et al. The BRCA1-D11q alternative splice isoform bypasses germline mutations
and promotes therapeutic resistance to PARP inhibition and cisplatin. Cancer Res 2016;76:2778-90.
71. García-Becerra R, Santos N, Díaz L, Camacho J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling
pathways, miRNAs and genetically based resistance. Int J Mol Sci 2012;14:108-45.